New LaunchJun 16, 2026, 07:00 AM
Avalo Therapeutics to submit IND for AVTX-010 in H1 2027
AI Summary
Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with plans to submit an Investigational New Drug (IND) application in the first half of 2027. AVTX-010 is designed to extend dosing intervals and has potential for hidradenitis suppurativa (HS) and other inflammatory disorders, building on the positive Phase 2 data of abdakibart. The company also plans to advance abdakibart into a pivotal Phase 3 registrational program, supported by recent financing and productive engagement with the FDA for AVTX-010.
Key Highlights
- Avalo Therapeutics advances AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody.
- Company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027.
- AVTX-010 is designed for extended dosing intervals for hidradenitis suppurativa (HS) and other inflammatory disorders.
- The advancement builds on positive abdakibart Phase 2 LOTUS topline data.
- Avalo Therapeutics will also advance abdakibart into a pivotal Phase 3 registrational program.
- Productive engagement with FDA enables a streamlined path for AVTX-010 to first-in-human studies.
Price Impact
More from AVTX